

AMENDMENTS TO THE CLAIMS

1. (Currently amended) Pharmaceutical composition for the treatment of acute and/or chronic pain comprising calcium channel blockers ~~which~~ that are capable of blocking voltage-dependent calcium channels.

2. (Original) Pharmaceutical composition as defined in claim 1 wherein the calcium channel is a T-type or L-type channel.

3. (Currently amended) Pharmaceutical composition as defined in claim 1 ~~or 2~~ for the treatment of allodynia or hyperalgesia.

4. (Currently amended) Pharmaceutical composition according to ~~any one of claims 1 to 3~~ claim 1 wherein the calcium channel blocker is mibefradil, its pharmaceutically acceptable analogues, salts or esters or a dihydropyridine.

5. (Currently amended) Pharmaceutical composition according to claim 1 for the treatment of pain associated with rheumatoid arthritis, cancer, injuries, back pain, herpes zoster and post-operative pain.

6. (Currently amended) Pharmaceutical composition according to ~~any one of claims 1 to 5~~ claim 1 for the topical, oral, parenteral, inhalative or intranasal administration.

7. (Original) Pharmaceutical composition according to claim 6 in form of an ointment, gel, crème or a solution or suspension, or plaster.

8. (Original) Pharmaceutical composition according to claim 6 in form of a nasal spray or inhalator.

9. (Currently amended) Method for the systemic therapy of pain, comprising administering a Pharmaceutical pharmaceutical composition according to any one of claims 1 to 3 for the systemic therapy of pain comprising calcium channel blockers that are capable of blocking voltage-dependent calcium channels.

10. (Currently amended) Pharmaceutical composition according to ~~any one of claims 1 to 3 characterised in that~~ claim 1 wherein the composition is in a drug form for oral administration, wherein the form is selected from the group consisting of a tablet, a capsule, a coated tablet, a granulate, a juice, a syrup, a suspension, and a solution. ~~tables, capsules, coated tablets, granulates, juice, syrup, suspensions or solutions are used as oral forms of application.~~

11. (Currently amended) Pharmaceutical composition according to ~~any one of claims 1 to 3 characterised in that~~ claim 1 wherein the drug form used is formed of comprises ~~biologically utilizable or biodegradable substances wherein the biological materials are selected from the group consisting of~~ proteins or proteides, lipids or lipoids, carbohydrates, or polysaccharides or mixtures of several of such materials and mixtures thereof.

12. (Currently amended) Pharmaceutical composition according to ~~any one of claims 1 to 3 characterised in that additionally~~ claim 1 which further comprises ~~one other pain killer is used.~~

13. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the other pain killer ~~used in combination~~ is selected from the group consisting of an NSAID, a 5HT_{1D} agonist, a dopamin D₂ receptor antagonist, a secale alkaloid, a beta blocker, a calcium channel blocker ~~or~~, and a neurokinin antagonist.

14. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the NSAID is ibuprofen, meoxicam, indomethacin or naproxen.

15. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the 5HT_{1D} agonist is sumatriptan, MK-452, naratriptan or 311C.

16. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the dopamin D₂ receptor antagonist is metoclopramid.

17. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the secale alkaloid is ergotamin, dihydroergotamin or metergolin.

18. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the beta blocker is propranolol or metoprolol.

19. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the calcium channel blocker is flunarizin or lomerizin.

20. (Currently amended) Pharmaceutical composition according to claim 12 ~~characterised in that~~ wherein the other pain killer ~~to be administered in combination~~ is

selected from the group consisting of acetylsalicylic acid, paracetamol, clonidin, methysergid, dotarizin, lisurid, pizotifen, valproat, aminotraptilin CP-122,288-~~or~~, and UK 116,044.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100